ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Advanced Search

Clinical Utility of a Pharmacogenomic Testing Tool among Kidney Transplant Recipients

S. LeCorchick, L. Lindberg, W. Stapley, S. Anand, D. Morris, T. Srinivas

Kidney/Pancreas Transplant Program, Intermountain Medical Center, Murray, UT

Meeting: 2019 American Transplant Congress

Abstract number: D214

Keywords: Drug interaction, Genomics, Immunosuppression, Kidney transplantation

Session Information

Date: Tuesday, June 4, 2019

Session Name: Poster Session D: Non-Organ Specific: Pharmacogenomics / Pharmacokinetics

Session Time: 6:00pm-7:00pm

 Presentation Time: 6:00pm-7:00pm

Location: Hall C & D

Related Abstracts
  • Target Tacrolimus Troughs and CYP3A5 Polymorphisms Do Not Predict Therapeutic Drug Exposure in African American and Caucasian Renal Transplant Recipients
  • Association of CYP3A5*3*6*7 Metabolic Composites to Tacrolimus Pharmacokinetics in African American and Caucasian Renal Transplant Recipients

*Purpose: Therapeutic drug monitoring (TDM) for tacrolimus (Tac) is the cornerstone of clinical workflow in the transplant clinic. We report on the clinical implementation of, Rx Match®, a DNA testing platform that measures, analyzes, and interprets a patient’s DNA to determine what medications and dosage selections are appropriate based on genetic information in a kidney transplant recipient population.

*Methods: RxMatch® provides information about CYP2C19, CYP2C9, CYP2D6, CYP3A4, and CYP3A5. In addition to providing information about a gene’s activity this test also provides specific recommendations for medication dosing and expected side effect severity. It also provides information on genes affecting thrombosis risk, including Factor V Leiden and VKORC1 activity. In July 2018 we implemented a new process to screen patients in work-up for kidney transplant with this assay. RxMatch® was obtained by cheek swab in the transplant clinic at the pre-operative visit or during the transplant admission.

*Results: 14 patients received testing and were included. 7 patients were classified based on CYP3A5 polymorphism as intermediate metabolizers (1 allele with normal activity and 1 allele with little or no activity) and 7 patients were classified based poor metabolizers (2 alleles showing little or no activity) (See Figure below for sample test readout). All patients with intermediate CYP3A5 activity were found to have *1D|*3A, *1A|*3C, *1A|*3A, or *1D|*3C alleles. Patients with poor CYP3A5 activity were found to have *3A|*3A, *3C|*3C, or *3A|*3C. 3 intermediate metabolizers had acute cellular rejection and 1 intermediate metabolizer had mixed cellular/antibody mediated rejection within the first 3 months of transplant. 1 poor metabolizer had acute cellular rejection in the first 3 months of transplant. Of note, in addition to immunosuppression, 5 of the intermediate metabolizers and 2 of the poor metabolizers were found to have decreased metabolism of tramadol to the active form with increased risk of pharmacologic failure. Test results were available to the transplant pharmacists within 72 hours of ordering.

*Conclusions: A patient specific genomic test can be used in clinical practice to help guide medication therapy in kidney transplant recipients over and above measuring blood concentrations of immunosuppressants. Such an approach is actionable in the routine workflow of a transplant program and has potential to personalize pharmacotherapy beyond immunosuppression and minimize drug-drug interactions, reduce side effects, and therapeutic failure.

 border=

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

LeCorchick S, Lindberg L, Stapley W, Anand S, Morris D, Srinivas T. Clinical Utility of a Pharmacogenomic Testing Tool among Kidney Transplant Recipients [abstract]. Am J Transplant. 2019; 19 (suppl 3). https://atcmeetingabstracts.com/abstract/clinical-utility-of-a-pharmacogenomic-testing-tool-among-kidney-transplant-recipients/. Accessed February 27, 2021.

« Back to 2019 American Transplant Congress

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • A Decade of Donor-Derived Disease: A Report of the OPTN Ad Hoc Disease Transmission Advisory Committee (DTAC).
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Kidney Dialysis after Heart Transplantation: The Short and Long Term Outcomes
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Penis Transplantation: First U.S. Experience.
  • A Decade of Donor-Derived Disease: A Report of the OPTN Ad Hoc Disease Transmission Advisory Committee (DTAC).
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Penis Transplantation: First U.S. Experience.
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Evidence of a Clinically Significant Drug-Drug Interaction between Cannabidiol and Tacrolimus: A Case Report
  • Kidney Dialysis after Heart Transplantation: The Short and Long Term Outcomes

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2021 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.